Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of “Reduce” from Brokerages

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has earned an average recommendation of “Reduce” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $22.00.

Several research firms have recently weighed in on AMPH. Wells Fargo & Company reissued an “equal weight” rating and set a $19.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Thursday, May 14th. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 11th. Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research cut Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, June 22nd. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th.

Amphastar Pharmaceuticals Trading Down 0.2%

Shares of Amphastar Pharmaceuticals stock opened at $19.59 on Friday. Amphastar Pharmaceuticals has a fifty-two week low of $16.65 and a fifty-two week high of $31.26. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79. The firm has a market cap of $863.72 million, a price-to-earnings ratio of 11.80, a price-to-earnings-growth ratio of 3.86 and a beta of 0.89. The business has a fifty day simple moving average of $19.24 and a 200-day simple moving average of $22.04.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.The business had revenue of $171.17 million during the quarter, compared to analyst estimates of $173.46 million. On average, equities analysts forecast that Amphastar Pharmaceuticals will post 2.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth approximately $2,504,000. Denali Advisors LLC grew its position in Amphastar Pharmaceuticals by 56.9% during the fourth quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock valued at $5,671,000 after purchasing an additional 76,765 shares in the last quarter. Bridge City Capital LLC grew its position in Amphastar Pharmaceuticals by 72.8% during the fourth quarter. Bridge City Capital LLC now owns 235,485 shares of the company’s stock valued at $6,306,000 after purchasing an additional 99,227 shares in the last quarter. TD Asset Management Inc increased its stake in Amphastar Pharmaceuticals by 1.6% in the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock valued at $52,571,000 after buying an additional 31,160 shares during the period. Finally, Cibc World Market Inc. purchased a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $1,666,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.